NuCana (NASDAQ:NCNA) Shares Up 0.8% – What’s Next?

Shares of NuCana PLC Sponsored ADR (NASDAQ:NCNA) shot up 0.8% during mid-day trading on Thursday. The stock traded as high as $1.34 and last traded at $1.32. Approximately 9,226 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 88,672 shares. The stock had previously closed at $1.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a report on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, NuCana has a consensus rating of “Sell”.

NuCana Stock Performance

The stock has a market capitalization of $5.49 million, a P/E ratio of -0.35 and a beta of 2.23. The business has a fifty day simple moving average of $1.39 and a 200-day simple moving average of $1.69.

NuCana (NASDAQ:NCNA) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($2.65) by $1.66.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies.

NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent.